鶹ֱ & Lardner LLP partner Michele Simkin insights from a recent firm health care and life sciences webinar are quoted in the PharmaVoice article, ““
During 鶹ֱ’s “GLP-1 Drugs in Focus: Trends, Needs, and What’s Next” webinar in September 2025, Simkin highlighted the success of GLP-1 drugs. “They have phenomenal effectiveness,” she underscored.
In terms of where the GLP-1 market may be headed, Simkin said that the drugs can also help “improve patient eligibility for surgeries and transplants by helping people meet BMI requirements.” She added that companies are also pursuing combination drugs that add a GLP-1 to another medication, or more potent products, including dual and triple agonists.
